Cyclacel Pharmaceuticals, Inc. (CYCC) Message Board
-
phase 3 trial will be completed at the end of 2014
so they still have along time to complete.
-
good or bad?
-
It is under SPA. go and find what SPA means.
Sentiment: Hold
- 2 Replies to bull_finder
-
That's Good it will give us time to buy more to get funds available like I did with MDVN,ARNA,VVUS,OREX,SPRT but few skyrocket in Phase 3 process leading to FDA approval and if it has a good chance of getting approval it will be minumum 400 to 700 million market cap. But, if it goes lower would be a great gamble because the most money I ever made was with ARNA,SRPT,SVA when I took avantage of prices way below market cap. of others until you know exactly sure there was no way of getting approval like in the case of VVUS and ARNA which was a DUH! 1.5 Billion market cap verus 100 million market cap and now finfing out ARNA is the better drug.....I will invets my money until I see 200 million market cap and maybe much more with CYCC if companies like SNSS and PPHM are around those valuactions already.....
-
Yea #$%$ are you talking about?? Special Protocol!! What the hell are you talking about?? The Seamless Trial is not going until 2014... Seliciclib is the other compound which is going to finish Phase II for NSCLC... Get your info straight guy..
-
Remember sapacitabine is under spa (special protocol assessment). This means that the company can receive the stamp, without complete data or statistical analysis of data from the SEAMLESS trials.
So, if tomorrows data is good, it can fly on Monday.Sentiment: Hold
-
Remember sapacitabine is under SPA (special protocol assessment). This means that the company can receive approval without complete data or statistical analysis of data from the SEAMLESS trials.
So, if tomorrows data is good, it can fly on Monday.Sentiment: Hold
-
Remember sapacitabine is under FDA SPA (special protocol assessment). This means that the company can receive FDA approval without complete data or statistical analysis of data from the SEAMLESS trials.
So, if tomorrows data is good, it can fly on Monday.Sentiment: Hold
-
Could you show us your link, where this information comes from?
Sentiment: Hold
- 1 Reply to gerald.gaffey
-
Cyclacel is still enrolling patients into its pivotal Phase III trial (called the "Seamless" trial), which will measure a combination of sapacitabine and decitabine against decitabine (a compound that is commonly used to treat MDS/AML). Acute myeloid leukemia isn't a very common form of cancer, but the likelihood of approval is very high due to the FDA's SPA agreement with Cyclacel, which allows for approval given that the drug can provide statistically significant and positive results. The market hasn't fully priced this into the value of sapacitabine, but Seamless is expected to take until late 2014 to reach primary completion.
-